Ascendis Pharma AS【ASND】銘柄情報

Ascendis Pharma AS (ASND) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

274.50

( 2.51% )

買値

201.51

売値

441.36

出来高

552,496

265.755 日の範囲 274.89

160.86 52 週間の範囲 274.745

時価総額

17.05B

前日終値

267.79

始値

270.90

時刻

274.5

最終取引時間

財務取引量

US$ 149,205,092

VWAP

270.0564

平均取引量 (3 か月)

US$ 815,702

発行済株式数

62,111,595

配当利回り

PER

29.26

1 株当たり利益 (EPS)

8.04

歳入

865.78M

純利益

495.93M

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a onc... Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

ascendispharma.com

本社

Hellerup, Denmark

設立

2026

Ascendis Pharma AS is listed in the Healthcare sector of the ナスダック市場 with ticker ASND. The last closing price for Ascendis Pharma AS was US$267.79. Over the last year, Ascendis Pharma AS shares have traded in a share price range of US$ 160.86 to US$ 274.745.

Ascendis Pharma AS currently has 62,111,595 shares in issue. The market capitalisation of Ascendis Pharma AS is US$17.05 billion. Ascendis Pharma AS has a price to earnings ratio (PE ratio) of 29.26.

全体の流れ

ブルリッシュ

ネットプレミアム

215k

Calls / Puts

100.00%

買い / 売り

100.00%

OTM / ITM

0.00%

Sweeps比率

0.00%

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial

Data presented during ICCBH 2026 showed that improvements in tibial-femoral angle (TFA), a measure of lower...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®

COPENHAGEN, Denmark, June 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced...

Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026

COPENHAGEN, Denmark, June 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

Multi-organ system and quality-of-life benefits sustained through three and a half years 86% response rate for...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism

– Multi-organ system and quality-of-life benefits sustained through five years of treatment – 82% response...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	36.45	15.3119092628	238.05	274.745	235.51	1862128	262.10185088	CS
4	56.84	26.114122944	217.66	274.745	203.8	971016	242.57955222	CS
12	41.3	17.7101200686	233.2	274.745	203.8	797406	237.37753302	CS
26	61.66	28.9701183988	212.84	274.745	193.03	722739	231.19664373	CS
52	104.31	61.2903225806	170.19	274.745	160.86	614574	217.32374458	CS
156	185.12	207.115685836	89.38	274.745	85.285	506069	166.37305655	CS
260	139.15	102.807536018	135.35	274.745	61.5791	473954	144.2837744	CS